Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort …
M Tamiya, A Tamiya, K Hosoya, Y Taniguchi… - Investigational new …, 2019 - Springer
Objectives As first line therapy, pembrolizumab provides longer progression free survival
(PFS) and overall survival (OS) than platinum doublets in programmed death ligand 1 (PD …
(PFS) and overall survival (OS) than platinum doublets in programmed death ligand 1 (PD …
Real-world efficacy of first-line pembrolizumab in patients with advanced or recurrent non–small-cell lung cancer and high PD-L1 tumor expression
Y Tambo, T Sone, K Shibata, K Nishi, H Shirasaki… - Clinical Lung Cancer, 2020 - Elsevier
Background In clinical trials, first-line treatment with pembrolizumab improved overall
survival (OS) in patients with advanced non–small-cell lung cancer (NSCLC) with a …
survival (OS) in patients with advanced non–small-cell lung cancer (NSCLC) with a …
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study
NB Leighl, MD Hellmann, R Hui… - The Lancet …, 2019 - thelancet.com
Background The anti-programmed death 1 monoclonal antibody pembrolizumab has shown
antitumour activity and is a first-line and second-line treatment option for patients with …
antitumour activity and is a first-line and second-line treatment option for patients with …
[HTML][HTML] Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
Background Pembrolizumab improved survival as first-and second-line therapy compared
with chemotherapy in patients with highly programmed death ligand 1 (PD-L1) expressing …
with chemotherapy in patients with highly programmed death ligand 1 (PD-L1) expressing …
Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non–small-cell lung cancer and programmed death ligand-1 tumor …
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …
report, typically based on the primary end point, may be published when key planned co …
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled …
H Borghaei, CJ Langer, L Paz‐Ares… - Cancer, 2020 - Wiley Online Library
Background Pembrolizumab plus platinum‐based chemotherapy has demonstrated
improved clinical outcomes over chemotherapy alone in patients with previously untreated …
improved clinical outcomes over chemotherapy alone in patients with previously untreated …
Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer
M Reck, D Rodríguez-Abreu… - … England Journal of …, 2016 - Mass Medical Soc
Background Pembrolizumab is a humanized monoclonal antibody against programmed
death 1 (PD-1) that has antitumor activity in advanced non–small-cell lung cancer (NSCLC) …
death 1 (PD-1) that has antitumor activity in advanced non–small-cell lung cancer (NSCLC) …
Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with PD-L1 tumor proportion …
M Reck, D Rodríguez–Abreu, AG Robinson… - Journal of Clinical …, 2019 - ascopubs.org
Purpose In the randomized, open-label, phase III KEYNOTE-024 study, pembrolizumab
significantly improved progression-free survival and overall survival (OS) compared with …
significantly improved progression-free survival and overall survival (OS) compared with …
[HTML][HTML] Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression
Background In non-small-cell lung cancers with programmed death-ligand 1 (PD-L1)
expression on≥ 50% of tumor cells, first-line treatment with the PD-1 inhibitor …
expression on≥ 50% of tumor cells, first-line treatment with the PD-1 inhibitor …
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
F Facchinetti, G Mazzaschi, F Barbieri… - European Journal of …, 2020 - Elsevier
Background Pembrolizumab is the first-line standard of care for advanced non–small cell
lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS)≥ 50%. Eastern …
lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS)≥ 50%. Eastern …